Targeted cancer therapies attempt to hit the bull's-eye.
Miller
M
M
D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism; D016503:Drug Delivery Systems; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008081:Liposomes; D009316:National Institutes of Health (U.S.); D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000187:drug effects*; D018005:Receptors, Vasoactive Intestinal Peptide / Q000187:drug effects; D000068878:Trastuzumab; D014481:United States; D015854:Up-Regulation / Q000187:drug effects
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D008081:Liposomes; D018719:Erb-b2 Receptor Tyrosine Kinases; D018005:Receptors, Vasoactive Intestinal Peptide; D000068878:Trastuzumab